Company Description
Silk Road Medical, Inc operates as a medical device company in the United States.
The company offers various products for the treatment of carotid artery disease called transcarotid artery revascularization (TCAR).
Its products comprise ENROUTE Transcarotid Neuroprotection System that is used to directly access the common carotid artery and establish temporary blood flow reversal; ENROUTE Transcarotid Stent System for transcarotid access; ENHANCE Transcarotid Peripheral Access Kit, which is used to gain initial access to the common carotid artery; ENROUTE 0.014 Guidewire for atraumatic vessel navigation and target lesion crossing for delivery of interventional devices; and ENROUTE Enflate Transcarotid RX Balloon Dilation Catheter, a transcarotid rapid exchange balloon for the TCAR procedure.
The company was incorporated in 2007 and is headquartered in Sunnyvale, California.
Country | United States |
Founded | 2007 |
IPO Date | Apr 4, 2019 |
Industry | Medical Devices |
Sector | Healthcare |
Employees | 474 |
CEO | Charles S. McKhann |
Contact Details
Address: 1213 Innsbruck Dr. Sunnyvale, California 94089-2918 United States | |
Phone | (650) 566-9060 |
Website | silkroadmed.com |
Stock Details
Ticker Symbol | SILK |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
IPO Price | $20.00 |
CIK Code | 0001397702 |
CUSIP Number | 82710M100 |
ISIN Number | US82710M1009 |
Employer ID | 20-8777622 |
SIC Code | 3841 |
Key Executives
Name | Position |
---|---|
Charles S. McKhann | Chief Executive Officer |
Lucas W. Buchanan | Chief Financial Officer and Chief Operating Officer |
Kevin M. Klemz | EVice President, Chief Legal Officer and Secretary |
Andrew S. Davis | Chief Commercial Officer |
Richard M. Ruedy | Executive Vice President of Clinical, Regulatory Affairs and Quality Assurance |
Mhairi L. Jones | Chief Accounting Officer and Vice President of Finance |
Tammy Leitsinger | Compliance Officer and Vice President of Medical Affairs |
Jorge O'Hara | Vice President of Marketing, Business Development and Strategy |
Alison Highlander | Vice President of Human Resources |
Dr. Sumaira MacDonald M.D., Ph.D. | Executive Medical Director |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Jul 1, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Jun 20, 2024 | 8-K | Current Report |
Jun 18, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
Jun 18, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
Jun 18, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
Jun 18, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
Jun 18, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
Jun 18, 2024 | 8-K | Current Report |
May 30, 2024 | SD | Form - SD |
May 7, 2024 | 10-Q | Quarterly Report |